

EN

E-002574/2025

Answer given by Executive Vice-President Fitto
on behalf of the European Commission
(8.8.2025)

The following Member States purchased COVID-19 vaccines from European Structural and Investment (ESI) Funds, partially using their respective REACT-EU envelopes: Estonia, Hungary, Luxemburg, Italy, Malta, Portugal, Slovakia and Spain. France did not use ESI Funds for the purchase of COVID-19 vaccination doses in 2023. The Commission does not have information on other EU instruments being used for vaccine purchases in Member States.

The target value of COVID-19 vaccination doses for 2023 amounts to around 221 million doses¹. Member States will transmit the end-2023 final cumulative values of actual purchases only by 2026 to the Commission. This is due to a prolongation of the deadline to relieve the administrative burden on Member States' programme managing authorities. Until then the only values available are until the end of 2022, which is close to 110 million doses delivered in total.

The Advance Purchase and Purchase Agreements concluded between the Commission, on behalf of the Member States, and the vaccine manufacturers foresee that Member States order the vaccines under these contracts from the manufacturer, who issues invoices at the time of delivery. Hence no national or EU funds are engaged for vaccines that would not be delivered.

¹ <https://cohesiondata.ec.europa.eu/2014-2020-Indicators/COVID-19-vaccination-doses-CV63-2014-2020/kk2i-uh5n>.